Clinical trials: RhA - Rheumatoid Arthritis
Rheumatoid Arthritis
An Open Label Extension Study in Participants With Rheumatoid Arthritis
To evaluate the safety and tolerability of LY2127399 administered as subcutaneous injections for 48 weeks in participants with Rheumatoid Arthritis
- Trial name
- NCT00837811
- Testing
- LY2127399
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 182 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis (RA)
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including…
- Trial name
- NCT02955212
- Testing
- Upadacitinib
- Where
- 43 sites in Brazil, China and 1 more
- Volunteers
- 338 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)
This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by participants with the disease.
- Trial name
- NCT00132769
- Testing
- MK-0873
- Volunteers
- 106 people
- Sponsor
- Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Rheumatoid Arthritis
A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis
The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational…
- Trial name
- NCT06625242
- Testing
- Filgotinib Maleate
- Where
- 15 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Eisai Korea Inc.
Rheumatoid Arthritis
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.
- Trial name
- FILOSOPHY (NCT04871919)
- Testing
- Filgotinib
- Where
- 89 sites in Belgium, Germany and 4 more
- Volunteers
- 1,304 people
- Sponsor
- Alfasigma S.p.A.
Rheumatoid Arthritis
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in subjects with moderate to severe Rheumatoid…
- Trial name
- NCT01936181
- Testing
- Remicade (infliximab), SB2 (proposed biosimilar to infliximab)
- Where
- 2 sites in Bulgaria, Lithuania
- Volunteers
- 584 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior…
- Trial name
- NCT00049751
- Testing
- Adalimumab
- Where
- 54 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS
This single arm, open-label study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to non-biologic and/or…
- Trial name
- NCT01149057
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 16 sites in Israel
- Volunteers
- 145 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-40346527 200 mg/day (100 mg twice daily) for 12 weeks, compared with placebo, in patients with active rheumatoid arthritis (RA) despite…
- Trial name
- NCT01597739
- Testing
- JNJ-40346527
- Where
- 32 sites in Argentina, Bulgaria and 8 more
- Volunteers
- 96 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis
A study comparing the usability of the Autoinjector and Pre-filled Syringe of SB4 in Subjects with Rheumatoid Arthritis.
- Trial name
- NCT03193957
- Testing
- Etanercept, Autoinjector
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy…
- Trial name
- NCT00195702
- Testing
- Adalimumab
- Where
- 87 sites in United States, Canada
- Volunteers
- 619 people
- Sponsor
- Abbott
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
This study [contRAst 1 (201790: NCT03980483)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult…
- Trial name
- contRAst 1 (NCT03980483)
- Testing
- GSK3196165 (Otilimab), Tofacitinib 5 mg
- Where
- 76 sites in China, Hungary and 8 more
- Volunteers
- 1,537 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Vasculitis With Rheumatoid Arthritis of Knee, Unilateral Post-Traumatic Osteoarthritis of Knee
JOURNEY II XR Safety and Effectiveness PMCF
This study was designed to demonstrate the safety and performance of the JOURNEY II XR total knee system by evaluating implant survival rates at 10 years using Kaplan-Meier analysis.
- Conditions
- Rheumatoid Vasculitis With Rheumatoid Arthritis of Knee, Unilateral Post-Traumatic Osteoarthritis of Knee, Knee Osteoarthritis, Degenerative Arthritis Peripheral Joint
- Trial name
- NCT03136887
- Testing
- JOURNEY II XR Total Knee System
- Where
- 14 sites in United States
- Volunteers
- 176 people
- Sponsor
- Smith & Nephew, Inc.
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Lymphoma
An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.
The purpose of this study is to examine the association with EBV infection, monitor the occurrence of lymphoma and assess lymphoma risk in patients with rheumatoid arthritis and/or Crohns disease and you have taken infliximab.
- Trial name
- NCT00440817
- Testing
- No intervention
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Rheumatoid Arthritis
A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates
The study is being conducted to assess the effect of BMS-986142 on the single-dose PK parameters of montelukast, flurbiprofen, omeprazole, midazolam, and digoxin, probe drugs for (cytochome P450) CYP2C8, CYP2C9, CYP2C19, CYP3A4…
- Trial name
- NCT02762123
- Testing
- BMS-986142 200mg, BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin), BMS-986142 350mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This randomized, double-blind, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with rheumatoid…
- Trial name
- NCT01399697
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 54 sites in Spain
- Volunteers
- 261 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
This is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to evaluate clinical remission and…
- Trial name
- New Indices (NCT00793403)
- Testing
- As per routinary clinical care
- Where
- Italy
- Volunteers
- 293 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
ALX-0061 Phase I Bioavailability Study in Healthy Volunteers
The overall aims of the study are: To assess the bioavailability of single doses of ALX-0061, administered s.c. at three dose levels, using 2 corresponding single i.v. dose levels as reference.
- Trial name
- NCT02101073
- Testing
- ALX-0061
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.